Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00.Invest ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.

Allbirds (NASDAQ:BIRD – Get Free Report) had its target price lowered by investment analysts at Morgan Stanley from $12.00 to $8.00 in a research note issued to investors on Tuesday,Benzinga reports.